Related Experiment Videos
CD56+CD7+ stem cell leukemia/lymphoma with D2-Jdelta1 rearrangement
T Yoshida1, N Kimura, H Sawada
1First Department of Internal Medicine, Fukuoka University School of Medicine.
Internal Medicine (Tokyo, Japan)
|August 6, 1999
Summary
This study details three cases of CD56+CD7+ stem cell leukemia/lymphoma, revealing unique immunophenotypic and genetic characteristics. Findings suggest a potential common lymphoid precursor origin for these aggressive malignancies.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- CD56+CD7+ stem cell leukemia/lymphoma is a rare and aggressive hematologic malignancy.
- Understanding its cellular origin and characteristics is crucial for diagnosis and treatment.
Purpose of the Study:
- To characterize the immunophenotypic, morphologic, and genetic features of three patients with CD56+CD7+ stem cell leukemia/lymphoma.
- To investigate the potential cellular origin of these leukemia/lymphoma blasts.
Main Methods:
- Morphologic, karyotypic, immunophenotypic, and immunogenotypic analyses were performed on patient samples.
- Southern blot and polymerase chain reaction (PCR) were utilized for genetic analysis.
Main Results:
- Blasts were myeloperoxidase (MPO)-negative, CD7+, and CD56+, with variable expression of other lineage markers (B, myeloid, stem cell).
- All patients had an aggressive clinical course; phenotypes shifted upon relapse.
- Cytogenetic analysis revealed no common abnormal karyotype but showed T-cell receptor (TCR) gene rearrangements.
Conclusions:
- The findings suggest that CD56+CD7+ stem cell leukemia/lymphoma may arise from a common lymphoid precursor (T, NK, B cell) or a Natural Killer T (NKT) cell precursor.
- Further comprehensive analysis is warranted to confirm the cellular origin and implications for treatment.